HER-2 positivity, although more commonly associated with breast cancer, can drive tumor aggressiveness in colorectal cancer, making treatment more challenging. HER-2-positive, targeted therapies such as trastuzumab, pertuzumab, and lapatinib, often used in combination with chemotherapy, offer an effective alternative for patients resistant to standard treatments [7]. Here, ERBB2 is linked to breast cancer.